News & events

We are delighted to announce the appointment of Donmienne Leung, Director at AbbVie Ventures, to the Board of Directors at ThirtyFiveBio, alongside Annette Schwartz from AbbVie Inc. joining our scientific advisors. ThirtyFiveBio are better positioned than ever to accelerate our work and bring new solutions to patients who need them.

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK’s innovation agency.

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK’s innovation agency.

ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James Westcott, presented our groundbreaking data at AACR 2023 in a scientific poster. Our team and network of academic institutions, research organizations, and industry partners have been developing and testing our innovative approach of antagonising GPR35...

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023.